Intelligence · Clinical Pipeline
R&D Pipeline Programs
ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.
- Programs indexed
- 20,548
- Companies
- 1,769
- Drugs tracked
- 4,797
Quick answer
NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.
-
DAREON™-7: A study to test how well different doses of BI 764532 in addition to chemotherapy are tolerated by people with advanced neuroendocrine cancers
Boehringer Ingelheim
Extra-pulmonary neuroendocrine carcinoma (epNEC), Neuroendocrine carcinoma (NEC) with unknown primary site, pulmonary Large cell neuroendocrine carcinoma (LCNEC)
1 trial -
DAREON™-8: A study to test how well different doses of BI 764532 in addition to standard of care are tolerated by people with advanced small cell lung cancer
Boehringer Ingelheim
Extensive-stage small cell lung carcinoma (ES-SCLC)
1 trial -
DOSE-FINDING CLINICAL TRIAL TO EVALUATE OF INTESTINAL LACTASE ACTIVITY VIA ORAL GAXILOSE ADMINISTRATION IN HEALTHY ADULT VOLUNTEERS
Lacuna Pharma Pty Ltd
Hypolactasia
1 trial -
Delta-9-THC Low Dose
BRIGHT MINDS BIOSCIENCES INC.
Age-related Cognitive Decline
1 trial -
Dose Escalation Study with Bispecific Antibodies in Adult Patients with Lupus Nephritis
Lacuna Pharma Pty Ltd
Lupus Nephritis
1 trial -
Dose dense re-challenge of high dose methotrexate (hd-mtx) with glucarpidase (cpg2) for relapsed primary cns lymphoma (pcnsl): A phase 1 trial (METHOGLU)
Pari Pharma GmbH
Oncology: RELAPSED PRIMARY CNS LYMPHOMA
1 trial -
Dose escalation
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Poor Graft Function
1 trial -
Dose escalation of SA030
Suzhou Ribo Life Science Co.
Obese
1 trial -
Dose escalation trial of BNT152+153 in patients with cancer
BioNTech SE
Various solid tumors that are metastatic or unresectable
1 trial -
Dose of 60 mg/kg Fraction IV-1 Alpha1-Proteinase Inhibitor
Takeda
Alpha 1-Antitrypsin Deficiency
1 trial -
ETC-1002
Esperion Therapeutics
Safety Evaluation of Escalating Doses
1 trial -
Ebola Vaccine - low dose
United Therapeutics Europe Ltd
Ebola Virus Disease
1 trial -
Evaluating Bioequivalence of a Fixed Dose Combination versus Individual Tablets of Bempedoic Acid / Ezetimibe, and Atorvastatin.
Daiichi Sankyo
No medical condition.
1 trial -
Evaluating Bioequivalence of a Fixed Dose Combination versus Individual Tablets of Bempedoic Acid, Ezetimibe, and Atorvastatin.
Daiichi Sankyo
No medical condition.
1 trial -
Evaluating Bioequivalence of a Fixed Dose Combination versus Individual Tablets of Bempedoic Acid, Ezetimibe, and Rosuvastatin.
Daiichi Sankyo
No medical condition
1 trial -
Evaluating Bioequivalence of a Fixed Dose Combination versus Tablets of Bempedoic Acid / Ezetimibe and Rosuvastatin.
Daiichi Sankyo
No medical condition.
1 trial -
Evaluation of bioequivalence of two products containing 400 mg ibuprofen and 100 mg caffeine: Ibuprofen / Caffeine 400 mg / 100 mg coated granules (Test) vs. Thomapyrin TENSION DUO, 400mg / 100mg Filmtabletten (Reference). A monocentric, open, randomized, single dose, two-period, crossover trial in healthy volunteers
Lacuna Pharma Pty Ltd
No therapeutic indication in the current trial with healthy volunteers.
1 trial -
Evaluation of bioequivalence of two products containing 50 mg dimenhydrinate: Dimenhydrinate 50 mg (Test) vs. Vomex A 50 mg Lösung zum Einnehmen im Beutel (Comparator). A monocentric, open, randomized, single dose, two-period, crossover trial in healthy volunteers
Lacuna Pharma Pty Ltd
No therapeutic indication in the current trial with healthy volunteers.
1 trial -
Evaluation of bioequivalence of two products containing 600 mg ibuprofen: Ibuprofen Sopharma 600 mg film-coated tablets (Test) vs. Brufen 600 mg film-coated tablets (Comparator). A monocentric, open, randomized, single dose, two-period, crossover trial in healthy volunteers
Lacuna Pharma Pty Ltd
No therapeutic indication in the current trial with healthy volunteers.
1 trial -
Evaluation of the Effect of Food, Itraconazole, and Rifampicin on the Single-Dose Pharmacokinetics of Naronapride.
Dr. Falk Pharma GmbH
No medical condition.
1 trial -
Evaluation of the Effect of Itraconazole, Quinidine and Rifampicin on the Single-Dose Pharmacokinetics of ZED1227
Dr. Falk Pharma GmbH
No medical condition.
1 trial -
Evaluation of the bioavailability of two transdermal gel preparations containing 0.1% w/w estradiol under fasting conditions: Estradiol/INTERMED gel 0.1% w/w (Test) vs. ESTREVA® 0.1%, gel (Comparator). A monocentric, open, randomized, single dose, two-period, crossover trial in healthy postmenopausal women
Lacuna Pharma Pty Ltd
No therapeutic indication in the current trial with healthy volunteers.
1 trial -
Fixed dose combination Ciprofloxacin/Celecoxib
NeuroSense Therapeutics
ALS (Amyotrophic Lateral Sclerosis)
1 trial -
Food effect and single- and multiple-ascending dose clinical trial of DF2755A in healthy participants
Dompe' Farmaceutici S.p.A.
interstitial cystitis/bladder pain syndrome
1 trial
Frequently asked questions
What is the NovaPharmaNews pipeline directory?
It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.
Where does pipeline data come from?
Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.
How do I find pipeline programs by company or phase?
Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.
Data attribution and licensing: Data sources